Modality
Peptide
MOA
IL-17i
Target
FLT3
Pathway
Hedgehog
CTCLLGSHeart Failure
Development Pipeline
Preclinical
Jun 2020
→ Jun 2028
PreclinicalCurrent
NCT08419719
1,745 pts·LGS
2020-06→2028-06·Recruiting
1,745 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-242.2y awayInterim· LGS
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2028-06-24 · 2.2y away
LGS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08419719 | Preclinical | LGS | Recruiting | 1745 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |